145.12
price down icon1.18%   -1.735
 
loading
前日終値:
$146.85
開ける:
$146.73
24時間の取引高:
1.11M
Relative Volume:
0.22
時価総額:
$179.94B
収益:
$29.79B
当期純損益:
$9.22B
株価収益率:
19.75
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-1.62%
1か月 パフォーマンス:
-1.04%
6か月 パフォーマンス:
+2.53%
1年 パフォーマンス:
+22.72%
1日の値動き範囲:
Value
$144.65
$147.23
1週間の範囲:
Value
$142.60
$148.60
52週間の値動き範囲:
Value
$112.82
$157.29

Gilead Sciences Inc Stock (GILD) Company Profile

Name
名前
Gilead Sciences Inc
Name
セクター
Healthcare (1051)
Name
電話
(650) 574-3000
Name
住所
333 LAKESIDE DR, FOSTER CITY, CA
Name
職員
17,000
Name
Twitter
@GileadSciences
Name
次回の収益日
2026-10-29
Name
最新のSEC提出書
Name
GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GILD icon
GILD
Gilead Sciences Inc
145.12 179.94B 29.79B 9.22B 10.23B 7.3494
LLY icon
LLY
Lilly Eli Co
1,135.00 1.01T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
253.28 610.39B 97.93B 21.04B 17.80B 8.6278
ABBV icon
ABBV
Abbvie Inc
266.69 471.28B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
139.29 343.65B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
141.06 268.11B 54.66B 13.58B 16.05B 7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-07-21 ダウングレード Leerink Partners Outperform → Market Perform
2026-07-06 アップグレード HSBC Securities Hold → Buy
2026-05-20 アップグレード Maxim Group Hold → Buy
2026-03-10 開始されました Jefferies Buy
2026-02-20 開始されました Barclays Equal Weight
2026-02-11 繰り返されました Needham Buy
2026-01-07 再開されました UBS Buy
2025-11-24 再開されました Truist Buy
2025-11-13 開始されました Scotiabank Sector Outperform
2025-08-19 アップグレード Daiwa Securities Neutral → Outperform
2025-08-08 アップグレード Truist Hold → Buy
2025-07-25 アップグレード Needham Hold → Buy
2025-04-22 再開されました Cantor Fitzgerald Overweight
2025-03-04 繰り返されました Oppenheimer Outperform
2025-02-18 アップグレード Deutsche Bank Hold → Buy
2025-02-13 アップグレード DZ Bank Hold → Buy
2025-01-10 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-12-10 再開されました BofA Securities Buy
2024-11-15 開始されました Wolfe Research Outperform
2024-11-14 開始されました Citigroup Buy
2024-11-08 ダウングレード Maxim Group Buy → Hold
2024-10-21 アップグレード Leerink Partners Market Perform → Outperform
2024-10-17 開始されました Bernstein Outperform
2024-10-07 アップグレード Wells Fargo Equal Weight → Overweight
2024-07-08 アップグレード Raymond James Mkt Perform → Outperform
2024-05-01 繰り返されました Maxim Group Buy
2024-04-24 アップグレード HSBC Securities Reduce → Hold
2024-02-22 ダウングレード Truist Buy → Hold
2023-11-09 開始されました Deutsche Bank Hold
2023-09-08 アップグレード BofA Securities Neutral → Buy
2023-09-06 開始されました HSBC Securities Reduce
2023-07-24 繰り返されました Barclays Equal Weight
2023-05-16 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-28 再開されました Piper Sandler Overweight
2023-01-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2022-12-13 再開されました BofA Securities Neutral
2022-12-09 ダウングレード DZ Bank Buy → Hold
2022-10-31 アップグレード Barclays Underweight → Equal Weight
2022-10-28 繰り返されました BMO Capital Markets Market Perform
2022-10-28 繰り返されました Cowen Outperform
2022-10-28 繰り返されました JP Morgan Overweight
2022-10-28 繰り返されました Jefferies Buy
2022-10-28 アップグレード Piper Sandler Neutral → Overweight
2022-10-28 繰り返されました RBC Capital Mkts Outperform
2022-10-28 アップグレード Truist Hold → Buy
2022-10-28 繰り返されました Wells Fargo Equal Weight
2022-10-04 アップグレード JP Morgan Neutral → Overweight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-02-28 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-02-02 繰り返されました BMO Capital Markets Outperform
2022-02-02 繰り返されました BofA Securities Neutral
2022-02-02 繰り返されました RBC Capital Mkts Outperform
2022-02-02 繰り返されました Truist Hold
2022-02-02 繰り返されました Wells Fargo Equal Weight
2022-01-28 アップグレード Argus Hold → Buy
2022-01-06 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-12-09 再開されました Wells Fargo Equal Weight
2021-12-06 開始されました Goldman Neutral
2021-11-19 アップグレード BMO Capital Markets Market Perform → Outperform
2021-11-19 再開されました Piper Sandler Neutral
2021-10-20 再開されました Cowen Outperform
2021-07-30 繰り返されました BMO Capital Markets Market Perform
2021-07-30 繰り返されました RBC Capital Mkts Outperform
2021-04-01 アップグレード Bernstein Mkt Perform → Outperform
2021-03-30 アップグレード Redburn Neutral → Buy
2021-01-19 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-11-03 再開されました Morgan Stanley Equal-Weight
2020-10-28 開始されました UBS Neutral
2020-09-30 再開されました Jefferies Buy
2020-09-15 アップグレード Maxim Group Hold → Buy
2020-07-31 繰り返されました Credit Suisse Neutral
2020-07-31 繰り返されました Morgan Stanley Equal-Weight
2020-07-31 繰り返されました Piper Sandler Overweight
2020-07-31 繰り返されました RBC Capital Mkts Outperform
2020-07-31 繰り返されました SunTrust Hold
2020-07-31 繰り返されました Wells Fargo Equal Weight
2020-07-20 アップグレード Credit Suisse Underperform → Neutral
2020-06-03 アップグレード SVB Leerink Mkt Perform → Outperform
2020-05-26 アップグレード SunTrust Sell → Hold
2020-05-01 ダウングレード JP Morgan Overweight → Neutral
2020-05-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-01 ダウングレード SunTrust Hold → Sell
2020-04-27 ダウングレード UBS Buy → Neutral
2020-04-20 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-04-20 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-17 ダウングレード CFRA Hold → Sell
すべてを表示

Gilead Sciences Inc (GILD) 最新ニュース

pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences stock gains 2.57 percent after AI agreement expands - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Benzinga

Oct 07, 2026
pulisher
Oct 07, 2026

JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 - marketscreener.com

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences signs five-year DevOps agreement with Cognizant - Yahoo Finance

Oct 07, 2026
pulisher
Oct 06, 2026

Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences - PR Newswire

Oct 06, 2026
pulisher
Oct 06, 2026

Drugmaker Gilead gets AI support for selected tech programs under a five-year extension - Stock Titan

Oct 06, 2026
pulisher
Oct 05, 2026

12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC - MarketBeat

Oct 05, 2026
pulisher
Oct 05, 2026

Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support - ChartMill

Oct 05, 2026
pulisher
Oct 02, 2026

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool

Oct 02, 2026
pulisher
Oct 02, 2026

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Zacks Investment Research

Oct 02, 2026
pulisher
Oct 02, 2026

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Oct 02, 2026
pulisher
Oct 02, 2026

Under a prearranged trading plan, Gilead Sciences (GILD) CEO sells 15,000 shares. - Stock Titan

Oct 02, 2026
pulisher
Oct 02, 2026

Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch

Oct 02, 2026
pulisher
Oct 01, 2026

Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 01, 2026
pulisher
Oct 01, 2026

More Upside Awaits for Gilead Sciences Stock. Stay Invested. - Barron's

Oct 01, 2026
pulisher
Oct 01, 2026

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research

Oct 01, 2026
pulisher
Oct 01, 2026

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Oct 01, 2026
pulisher
Sep 30, 2026

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Zacks Investment Research

Sep 30, 2026
pulisher
Sep 30, 2026

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors - Yahoo Finance

Sep 30, 2026
pulisher
Sep 30, 2026

Gilead Sciences stock reports growth at EUR 133.42, plus 0.02 percent - AD HOC NEWS

Sep 30, 2026
pulisher
Sep 29, 2026

Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings - kalkine.ca

Sep 29, 2026
pulisher
Sep 28, 2026

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? - finance.yahoo.com

Sep 28, 2026
pulisher
Sep 28, 2026

Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? - Yahoo Finance

Sep 28, 2026
pulisher
Sep 28, 2026

Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? - finance.yahoo.com

Sep 28, 2026
pulisher
Sep 28, 2026

Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? - Yahoo Finance

Sep 28, 2026
pulisher
Sep 27, 2026

CEUX:GISd Dividend: Does Gilead Sciences Inc Pay a Dividend? - GuruFocus

Sep 27, 2026
pulisher
Sep 27, 2026

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? - finance.yahoo.com

Sep 27, 2026
pulisher
Sep 27, 2026

Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? - Yahoo Finance

Sep 27, 2026
pulisher
Sep 26, 2026

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts - MarketBeat

Sep 26, 2026
pulisher
Sep 25, 2026

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. - MarketBeat

Sep 25, 2026
pulisher
Sep 24, 2026

Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 24, 2026
pulisher
Sep 24, 2026

Gilead Sciences stock slips 0.85 percent ahead of the open - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 23, 2026

Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha

Sep 23, 2026
pulisher
Sep 22, 2026

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool

Sep 22, 2026
pulisher
Sep 22, 2026

Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 22, 2026
pulisher
Sep 22, 2026

State Street Corp Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat

Sep 22, 2026
pulisher
Sep 22, 2026

Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Sep 22, 2026
pulisher
Sep 22, 2026

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities - GlobeNewswire Inc.

Sep 22, 2026
pulisher
Sep 21, 2026

THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database

Sep 21, 2026
pulisher
Sep 21, 2026

Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today - Benzinga

Sep 21, 2026
pulisher
Sep 21, 2026

Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 20, 2026

Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries? - Yahoo Finance

Sep 20, 2026
pulisher
Sep 17, 2026

[Press releases] Gilead Sciences provides updates on access to lenacapavir for HIV prevention - European AIDS Treatment Group

Sep 17, 2026
pulisher
Sep 17, 2026

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance

Sep 17, 2026
pulisher
Sep 15, 2026

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Yahoo Finance

Sep 15, 2026
pulisher
Sep 15, 2026

Gilead Sciences Inc's Dividend Analysis - Yahoo Finance

Sep 15, 2026
pulisher
Sep 15, 2026

Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean - Reuters

Sep 15, 2026
pulisher
Sep 14, 2026

Is Gilead Sciences (GILD) Reasonable Given Its Sales Base? - finance.yahoo.com

Sep 14, 2026

Gilead Sciences Inc (GILD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Gilead Sciences Inc (GILD) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Dickinson Andrew D
Chief Financial Officer
Sep 15 '26
Sale
145.29
3,000
435,870
164,096
ANDREW DICKINSON
Officer
Sep 15 '26
Proposed Sale
145.29
3,000
435,870
0
JOHANNA MERCIER
Officer
Sep 15 '26
Proposed Sale
144.22
3,000
432,646
0
Mercier Johanna
Chief Comm & Corp Aff Officer
Sep 15 '26
Sale
144.22
3,000
432,646
116,684
O'Day Daniel Patrick
Chairman & CEO
Sep 01 '26
Sale
148.64
15,000
2,229,592
577,133
WELTERS ANTHONY
Director
Aug 26 '26
Option Exercise
61.06
18,000
1,099,052
23,176
ANTHONY WELTERS
Director
Aug 26 '26
Proposed Sale
148.77
18,000
2,677,860
0
WELTERS ANTHONY
Director
Aug 26 '26
Sale
148.62
18,000
2,675,220
12,894
Bluestone Jeffrey
Director
Aug 20 '26
Sale
145.02
5,000
725,078
10,066
Bluestone Jeffrey
Director
Aug 20 '26
Option Exercise
67.04
5,000
335,207
11,882
NVO NVO
$37.53
price down icon 1.89%
PFE PFE
$27.58
price down icon 1.49%
$401.41
price down icon 2.83%
BMY BMY
$59.06
price down icon 1.07%
AZN AZN
$157.12
price down icon 1.87%
SNY SNY
$39.63
price down icon 1.41%
大文字化:     |  ボリューム (24 時間):